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Summary 
To characterize  the production of hyaluronate capsule  by the membrane-associated enzyme 
hyaluronate synthase (HAS), group A streptococci from a recent outbreak of acute rheumatic 
fever were mutagenized via Tn916 insertion.  Acapsular  transconjugants harboring multiple, 
nontandem copies of the transposon were identified and found to lack HAS activity (<1% of 
wild-type levels). Generalized transduction was then performed to determine which Tn916 insertion 
was responsible for the HAS- phenotype. These marker exchange experiments resulted in the 
isolation of two distinct classes of acapsular transductants, designated WF61 and WF62. Both 
transductants also lacked significant HAS activity,  and excision of the transposon from WF62 
restored capsular hyaluronate production. Southern analysis of WF61 DNA demonstrated a large 
deletion of genomic DNA adjacent to the Tn916 insertion. This deletion event is presumably 
responsible for the observed stability of the acapsular phenotype of WF61. Further analyses of 
transductant whole-cell DNA indicated that the transposon insertions of WF61 and WF62 were 
separated by 2.5 kb. These studies define a locus required for hyaluronate capsule production 
in group A  streptococci. Further genetic analysis of this locus has identified a gene required 
for HAS activity which was inactivated by Tn916 in WF62 and deleted in WF61. 
L 
ncefield group A streptococci (Streptococcus tTogenes) are 
human pathogens capable of causing a variety of infec- 
tions, as well as nonsuppurative sequelae such as acute rheu- 
matic fever and poststreptococcal glomerulonephritis. Many 
strains of both groups A and C streptococci are able to sur- 
round themselves with a capsule of hyaluronate (hyaluronic 
acid), with the former accounting for the majority of serious 
human infections. Group C streptococci are primarily animal 
pathogens, however, and are not known to initiate postinfec- 
tious sequelae. In addition to the major virulence factor M 
protein, which protrudes from the surface of group A strep- 
tococci (1), the hyaluronate capsule has also been implicated 
as a virulence factor (2,  3). 
During the last decade, a resurgence of acute rheumatic 
fever has been reported by several investigators (4). An en- 
hancement of some virulence factor(s) of the streptococci could 
explain the severe suppurative and nonsuppurative sequelae 
associated with these outbreaks. One notable characteristic 
of these group A streptococcal isolates was their highly mu- 
coid nature. Capsular hyaluronate is thought to endow group 
A streptococci with the ability to resist phagocytosis in mice 
(3, 5, 6). In contrast, in vitro studies demonstrated the pres- 
ence of a heat-labile component present in human blood (but 
absent from the blood of mice and rabbits)  that neutralized 
the antiphagocytic effect of the hyaluronate capsule (7, 8). 
Stollerman et al.  (9) showed, however,  that the sera from 
a small number of rabbits and humans were exceptions to 
this observation. More recently, Wessels et al. (2) constructed 
an acapsular  mutant to further investigate the role of the 
hyaluronate capsule  in  human infections.  These workers 
demonstrated, in contrast to the above studies, that the ability 
to survive in fresh human blood and the antiphagocytic na- 
ture of the Streptococci appeared to correlate with the pres- 
ence of a hyaluronate capsule. Therefore, the role of hyaluronate 
as a major virulence factor in humans is open to further ex- 
perimentation. 
Structural identity has been demonstrated between some 
bacterial capsules and components of mammalian tissue (10). 
Hyaluronate produced by groups A and C streptococci is chem- 
ically indistinguishable from that found in the connective tissue 
and biological fluids of mammals. This may account for the 
poor immunogenicity of hyaluronate (11). Antibodies that 
react with hyaluronate are present in low titer in both the 
sera of several animal species (12) and that from patients with 
systemic lupus erythematosus and poststreptococcal glomer- 
ulonephritis (13, 14). Furthermore, using encapsulated strep- 
tococcal or liposome-bound hyaluronate, Fillit et al. (15, 16) 
were able to induce a humoral immune response to hyaluronate 
in rabbits and mice, respectively. 
Hyaluronate is a linear  glycosaminoglycan composed of 
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acid ~  1-3 linked to N-acetylglucosamine. The hyaluronate 
synthase (HAS) 1 enzyme system, associated with the strep- 
tococcal membrane, produces the heteropolysaccharide from 
the precursors uridine  diphosphate  ghcuronic  acid (UDP- 
GlcUA) and UDP-N-acetylglucosamine (UDP-GlcNAc) (17). 
Although cell-free synthesis was demonstrated over 35 years 
ago (18), an understanding of the mechanism of hyaluronate 
biosynthesis remains incomplete.  A step towards characterizing 
this mechanism was achieved in the work of Triscott and van 
de Rijn (19) with  the digitonin-solubilization  of HAS ac- 
tivity from streptococcal membranes,  and optimization  of 
enzyme  activity  with  the  phospholipid  cardiolipin.  One 
reported purification of a group C  HAS protein (20) failed 
to demonstrate  a single purified protein with biosynthetic 
activity.  Attempts  by  our  laboratory  to  purify  HAS  to 
homogeneity have resulted in a concomitant loss of HAS ac- 
tivity.  Therefore,  final  purification  of an enzymatically ac- 
tive HAS remains  elusive. 
In the present study, an alternative strategy for character- 
ization of the streptococcal HAS was devised that involves 
the identification  and expression of the genes required for 
hyaluronate synthesis. Analysis of the HAS genes and con- 
struction of isogenic mutants would greatly aid in elucidating 
the mechanism  of hyaluronate biosynthesis,  and in further 
characterizing a streptococcal virulence factor., As a step to- 
wards these goals, mutants lacking HAS activity were iso- 
lated and characterized.  These experiments define a genetic 
locus required for hyaluronate  synthetic activity. 
Materials  and Methods 
Bacterial Strains, Media, and Antibiotics.  The bacterial strains used 
in these studies are listed in Table 1. Streptococci were confirmed 
to be of the Lancefield group A using specific antisera by precipitin 
assay (21). Unless otherwise  indicated,  streptococci were grown 
at 37~  in chemically defined media (CDM [22]) while Escherichia 
coli were grown by shaking at 37  ~ in Luria Bertani (LB) broth (23). 
For growth of streptococci on solid media, Todd Hewitt broth 
(Difco Laboratories, Detroit, MI) was supplemented with 1.5% 
agar. Growth of bacteria was measured by OD using a Spectronic 
20 (Bausch & Lomb, Inc., Rochester, NY) at a wavelength of 650 
nm. All strains were maintained frozen at  -80~  in media con- 
taining  50% glycerol 
When appropriate, antibiotics were used at the following con- 
centrations: streptococci, tetracycline (5/tg/ml), streptomycin (1,000 
/~g/ml); E. coli, tetracycline (10 #g/ml), ampicillin (50/xg/ml),  and 
chloramphenicol  (25 #g/ml). 
Spontaneous streptomycin-resistant group A streptococci were 
isolated by growing 5-ml cultures  of bacteria,  and plating  onto 
media containing  100/~g/ml  streptomycin.  Colonies resistant to 
100/~g/ml streptomycin were similary grown and plated on media 
supplemented with 1,000/~g/ml streptomycin. Two variants (WF14 
and WF13) resistant  to 1,000/~g/ml  streptomycin were derived 
in this fashion from WF50 and WF51, respectively. 
Plasmids and Purification of DNA.  Plasmids  used in this study 
1 Abbreviations used in thispaper: CDM, chemically defined media; GlcUA, 
glucuronic acid; HAS, hyahronate synthase; LB, Luria Bertani broth; 
ORF, open reading frame; SSP-PCR, single-specific-primer  polymerase 
chain reaction; UDP, uridine diphosphate. 
include pACYC184 ([241, kindly provided by F. Macrina) Virginia 
Commonwealth University, Richmond, VA, pUC18 (Bethesda Re- 
search Laboratories, Gaithersburg,  MD), and pBluescript II SK- 
(Stratagene Inc., La Jolla, CA). The chimeric plasmid pAM120 con- 
sists of Tn916 cloned into  the plasmid pGL101 (25). 
Plasmids were introduced into E. coli by the one step transfor- 
mation method (23). E. coli XL1-Bhe (Stratagene, Inc.) transformed 
with recombinant pBhescript plasmids were screened after plating 
on LB supplemented with 50/~m isopropyl-B-D-thiogalactopyrano- 
side (5 Prime-3 Prime, Inc., West Chester, PA), and 0.02% 5-bromo- 
4-chloro-3-indolyl-B-D-galactopyranoside (5 Prime-3 Prime, Inc.) 
to detect insertional activation of the lacZce gene. Plasmid DNA 
was purified by the alkaline lysis method (23), and DNA concen- 
trations were determined by measuring the absorbance at 260 nm. 
Whole-cell DNA was isolated from mutanolysin-treated group 
Astrepmcocci. Briefly, CDM (20 ml) supplemented with 20 mM 
glycine was inoculated with the appropriate culture and incubated 
overnight. The culture was PeUeted  and resuspended to 500/~1 total 
vol in TE-sucrose (10 mM tris [pH=7.2], 1 mM EDTA, and 25% 
sucrose). Mutanolysin (2 U/ml) and lysozyme (3.1  x  10  s U/ml) 
were added, and the mixture was incubated at 37~  for I h. The 
cells were then lysed with n-lauroyl sarcosine (1% final concentra- 
tion), and incubated with RNase A (20 U/ml) at 65~  for 30 rain. 
Next, the DNA mixture was incubated with pronase (100 U/ml) 
for 1 h at 37~  followed by extraction with phenol and chloro- 
form. After ethanol precipitation, the DNA was washed with 70% 
ethanol  and resuspended in distilled water (200/~1). 
Filter Matings.  Tn916 was transferred to group A streptococci 
as described by Franke and CleweU (26) with modifications. Briefly, 
cultures  of the recipient group A streptococci (grown in CDM 
containing  hyaluronidase [70 U/ml]) and the CGl10 donor were 
mixed at a ratio of 40:1, respectively, and deposited onto a filter 
membrane. The filters were incubated overnight and bacteria were 
then plated on solid media supplemented with tetracycline and strep- 
tomycin to select for transconjugants. 
Transductions.  Generalized transductions were performed using 
the streptococcal bacteriophage A25 as described by Caparon and 
Scott (27). M17 broth (Becton Dickinson Microbiology Systems, 
Cockeysville, MD) was substituted for the various liquid and solid 
media called for in the procedure. Dextrose (5% final concentra- 
tion) was added to agar plates when differentiation between mu- 
coid and nonmucoid  colonies was required. 
Hyaluronate Production.  Qualitative production  of hyaluronate 
capsule was monitored by India ink preparations (28). For confirma- 
tion  of hyaluronate synthase activity, membranes were prepared 
by phage lysin treatment  of group A streptococci, according to 
the procedure of van de Rijn (29). Enzyme solubilization and HAS 
activity were accomplished, as follows, by modifications of the pro- 
tocols described by Triscott and van de Rijn (19). 
Membranes (5 mg/ml) isolated from streptococci grown to the 
exponential  phase  were  sohbilized  using  0.5%  dodecyl-fl-n- 
maltoside in buffer A (0.05 M NaHPO4/KHzPO4,  pH 6.9, 0.15 
M NaC1, 10 mM MgC12, 5 mM dithioerythritol,  10% glycerol) 
at 4~  for 60 min with stirring. Insoluble membrane components 
were removed by sedimentation at 196,000 g for I h at 4~  The 
supernatant  that contained the HAS activity was then  stored at 
-70~  until use. 
Analysis of the transfer of UDP-[U-14C]glucuronic acid to hy- 
aluronic acid was monitored as follows. Membrane extracts (50/~1) 
were combined with reaction mixture (50/~1, containing 0.182/~mol 
dithioerythritol,  0.455/~mol  MgCI2, 0.6/~mol of UDP-GlcNAc, 
and  0.148 nmol of UDP-GlcUA [8.6  x  104 cpm]  in 47 mM 
NaHPO4/KHzPO4,  pH 6.9 buffer). All reactions were performed 
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terminated by the addition of 10% SDS (10 #1), followed by heating 
at 100~  for 2 min. Reaction rates were taken from the initial linear 
portion of the product versus time curves and were run in duplicate. 
For determination  of radioactivity incorporated  into the high 
molecular weight fraction, the reaction mixtures were loaded onto 
spin columns prepared from Sephadex G-50 in 1-ml plastic syringes 
(23). The eluted high molecular weight material was then mixed 
with Ecolume (ICN Biomedicals, Inc., Costa Mesa, CA), and in- 
corporated radioactivity was quantitated using a scintillation counter. 
Zero time controls were run to correct for residual radioactivity. 
Protein Determination.  Protein quantitation  was accomplished 
using the bicinchoninic  acid assay (BCA;  Pierce Chemical  Co., 
Rockford,  IL). Since buffer A contains a number of components 
that interfere with the BCA protein assay, all samples were treated 
as follows before analysis. Extracts  (75 #1) were mixed with ace- 
tone (300 #1) and incubated at 40C for 5 rain. The samples were 
then  sedimented at 13,000 g for 5 min and the supernatant  was 
discarded. The samples were next treated with absolute ethanol 
(100 #1) at 4~  for 3 min followed by resedimentation of the precipi- 
tate  and removal of the supernatant.  Finally, the samples were 
resuspended in 0.1 N NaOH (100 #1) and analyzed for protein con- 
tent. All samples were evaluated in duplicate using BSA as standard. 
DNA Manipulations.  DNA restriction  and modification  en- 
zymes were obtained from Promega Corp. (Madison, WI) and used 
in accordance  with the manufacturer's suggestions. DNA fragments 
were routinely separated by horizontal agarose gel electrophoresis 
and visualized by ethidium bromide staining (23). Restriction  or 
modification of isolated DNA fragments were performed in GTG 
Seaplaque agarose (FMC Bioproducts, Rockland,  ME) according 
to the manufacturer's recommendations. When required, DNA was 
further purified using the GeneClean kit (Bio 101, La Jolla, CA). 
DNA/DNA hybridizations were performed after transferring 
DNA from agarose gels to Nytran membranes (Schleicher & Schuell, 
Keene, NH) by capillary blot (23). DNA probes were labeled with 
c~-[32p]dCTP (NEN  Research  Products,  Boston,  MA)  using  a 
random primed DNA labeling kit (Boehringer Mannheim Biochem- 
icals, Inc., Indianapolis, IN). Hybridizations were performed using 
standard high  stringency conditions  (23). Bands were visualized 
by exposure of filters to Kodak XAR-5 film (Eastman Kodak Co., 
Rochester,  NY) at  -80~ 
PCR Amplification of  DNA Flanking Tn916.  S. pyogenes DNA 
flanking Tn916 was amplified by the single-specific-primer poly- 
merase chain reaction (SSP-PCR) method of Shyamala and Ames 
(30). PCR reactions were performed in a final volume of 100 #1 
containing 100 ng DNA template (40 ng restriction-digested traas- 
ductant  whole-ceU DNA ligated  to 60-ng  compatibly  digested 
pUC18 DNA), 1.0 #M oligomers, 1.0 #M concentration  of each 
deoxynucleoside triphosphates,  and 10 #1 Taq DNA polymerase 
10x buffer (Promega Corp.). 2 U of Taq DNA polymerase (Promega 
Corp.) was added to the reaction mixture upon reaching the dena- 
turing temperature of 93~  and the amplification was carried out 
for 30 cycles using a DNA Thermal  Cycler (Perkin Elmer-Cetus, 
Norwalk, CT).  The parameters for PCR consisted of denatura- 
tion (93~  for 1 rain, annealing (55~  for 3 min, and extension 
(70~  for 1 min. The plasmid-specific primer used was the M13 
(-47)  primer  (New  England  Biolabs, Inc.,  Beverly, MA). 
Transposon-specific primers  TNL1  (5'-TATAAAGCTTGAGAA- 
GCAACAGGAGCGTCTTGTTGC-Y)  and  TNR1  (5'-TATTA- 
AGCTTGACACCTCATTTTTTGAAGTGTCTAC-Y)  were syn- 
thesized based on the sequence of the Tn916 termini published by 
Clewell (31), and contained tailored HindlII restriction sites to facili- 
tate cloning  of PCR products. 
DNA Library Construction and Screening,  A genomic library of 
S. pyogenes  DNA was prepared using the Lambda Fix II/XhoI Par- 
tial Fill-in Vector Kit (Stratagene Inc.) according to the manufac- 
turer's  protocol.  Briefly, WF14 whole-cell  DNA  was partially 
digested with Sau3AI to yield restriction  fragments in the range 
of 12-24 kb, filled in with dGTP and dATP, and hgated to the 
)~ replacement vector arms. Recombinant phage were sdected using 
E. coli  P2392 (Stratagene Inc.) and recombinant clones were screened 
by plaque lift  hybridizations  (23). After two rounds  of plaque 
purification, the phage DNA was purified using the Lambdasorb 
phage absorbent protocol (Promega Corp.). 
Reversion to Capsule Production.  Because of the reported insta- 
bility of Tn916 in the absence of selective  pressure (25, 32), attempts 
were made to select for excision of the transposon from the locus 
required for capsule production.  Acapsular transductants were pas- 
saged by inoculation of a loopful of glycerol stock into 5-ml liquid 
media lacking tetracycline. The overnight culture was then diluted 
and plated onto medium lacking antibiotics. After overnight incu- 
bation at 37~  colonies were scored for capsule production.  As 
a control the glycerol stock was diluted, plated directly onto medium 
lacking antibiotics,  and similarly incubated and scored. 
Results 
Tn916 Mutagenesis of Group A  Streptococci.  To study cap- 
sule synthesis in these pathogenic streptococci, encapsulated 
S. pyogenes strains  were mutagenized  via transposon  inser- 
tion. The conjugative transposon TmOl6 was transferred from 
the group D streptococcal strain CGl10 into the streptomycin- 
resistant  group A  strains  WF13 and WF14.  The resultant 
transconjugants  were selected on medium containing both 
tetracycline (to select for Tn916) and streptomycin (to select 
against  CGl10). 
Transconjugants  were screened  for  nonmucoid  colonies 
which were then tested for capsule production by India ink 
staining.  Four unencapsulated  transconjugants (WF15, WF20, 
WF22, and WF35) were further characterized for this study. 
All acapsular mutants were confirmed to be of the Lancefield 
group A  by precipitin  reaction. 
Hyaluronate Synthase Assay of Transconjugants Lacking Cap- 
sule.  To ensure that loss of capsule correlated with loss of 
hyaluronate synthase activity, membranes from encapsulated 
strains and acapsular mutants were isolated, sdubilized, and 
assayed for production of radiolabeled high molecular weight 
hyaluronate. As expected, extracts from detergent-solubilized 
membranes  of encapsulated  group  A  streptococcal  strains 
(WF50 and WF51) and their streptomycin-resistant progeny 
(WF14 and WF13, respectively) were able to transfer gluc- 
uronic  acid from  UDP-glucuronic  acid to high  molecular 
weight polymer (Table 2; sp act 18,648;  21,910;  18,090; and 
23,942 pmol/h/mg  protein,  respectively).  In contrast,  ex- 
tracts  obtained  from  the  membranes  of the  transposon- 
inactivated mutants (WF15, WF20, WF22, and WF35) trans- 
ferred only background amounts of glucuronic acid to high 
molecular weight polymer (Table 2; sp act 59, 136, 125, and 
129 pmol/h/mg protein, respectively). Thus all of the acap- 
sular transconjugants expressed <1% of the HAS activity rel- 
ative to the parental  strains. 
Molecular Characterization of  Acapsular Transconjugants.  The 
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Strain  Description  Source 
S. pyogenes 
WF50  Encapsulated M type 18 clinical isolate  J.  Daly (4-50M) 
WF51  Encapsulated M type 18 clinical isolate  J.  Daly (ARF-8) 
WF13  Encapsulated Str  r derivative of WF51  This paper 
WF14  Encapsulated Str  r derivative of WFS0  This paper 
WF15  Acapsular transconjugant  derived from WF13,  multiple  This paper 
copies of Tn916 
Acapsular transconjugant  derived from WF13,  multiple 
copies of Tn916 
Acapsular transconjugant  derived from WF14,  multiple 
copies of Tn916 
Acapsular transconjugant  derived from WF14,  multiple 
copies of Tn916 
Acapsular transductant  derived from WF20,  ORFB::Tn916 
(contains deletion) 
Acapsular transductant  derived from WF22,  ORFA::Tn916 
Encapsulated revertant  of WF62,  Tc  r 
Encapsulated revertant  of WF62,  Tc  S 
WF20  This paper 
WF22  This paper 
WF35  This paper 
WF61  This paper 
WF62 
WF63 
WF64 
E. coli 
CG120 
P2392 
HB101 
XL1-Blue 
E. faecalis 
CG110 
DHI(pAM120),  contains Tn916 
Host for recombinant  h  phage 
Host for cloning pACYC184  plasmids 
Host  for cloning pBluescript plasmids 
Donates  Tn916 at high frequency 
This paper 
This paper 
This paper 
D. Clewell 
Stratagene Inc. 
Bethesda Research Laboratories 
Stratagene Inc. 
D. Clewell 
number of copies of Tn916 in the acapsular mutants was de- 
termined by Southern blot analysis of whole-cell DNA using 
32p-labeled  pAM120  (which  contains  a  cloned  copy  of 
Tn916). Since a single restriction site for HindlII exists  in 
the transposon,  digestion generates left and right arms of 
5.4 and 10.9 kb, respectively (33).  Therefore, chromosomal 
DNA digested with HindlII will display two junction frag- 
ments  for  each copy of Tn916.  No  hybridization  of the 
pAM120 probe was observed with WF51 DNA (Fig.  1 A, 
lane 1), but was observed with a positive control (pAM120; 
Fig,  1 A, lane 5). The WF20 transconjugant DNA (Fig.  1 
A,  lane  2)  possessed  six  hybridizing  HindlII  fragments 
('~17.5, 12.5, 11.5, 8.5, 6.3, and 5.8 kb), indicating that three 
copies of Tn916 reside in the WF20 genome. The three other 
acapsutar transconjugants also harbored multiple copies of 
Tn916 (e.g., WF15,  Fig.  1 B, lane 3). 
Transduction of Tn916-containing Loci into WF-50.  To es- 
tablish which Tn916 insertion was responsible for loss of cap- 
sule production and HAS activity, generalized transduction 
was performed using the streptococcal bacteriophage A25. 
WF50 was infected with lysates of A25 phage (that had been 
previously grown on WF20),  and plated on medium con- 
taining tetracycline to select for Tn916. Transductants appeared 
at a frequency of 1.5  x  IO-7/PFU phage, and both encap- 
sulated and unencapsulated derivatives were recovered. 
The exchange of single Tn916 insertions into the wild-type 
background was then demonstrated by hybridization of trans- 
ductant whole-cell DNA with the pAM120 probe (Fig.  1). 
Whole-cell DNA from a representative encapsulated trans- 
ductant  (Fig.  1 A,  lane 3)  displayed hybridizing HindlII 
junction fragments of 12.5 and 5.8 kb, compared with the 
17.5-  and 8.5-kb HindlII fragments of the unencapsulated 
transductant  WF61  (Fig.  1  A,  lane  4).  Both  pairs  of 
hybridizing junction fragments were evident in the total-cell 
DNA of the WF20 transconjugant from which they were 
derived (Fig.  1 A, lane 2). However, only the 17.5- and 8.5- 
kb pair of junction fragments cotransduced with the acap- 
sular phenotype. 
In a similar approach, a second acapsular mutant (desig- 
nated WF62)  was derived from the WF22 transconjugant 
by generalized transduction. WF62 whole-cell DNA con- 
tained a single copy of Tn916 with hybridizing HindlII junc- 
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Solubilized Streptococcal Membrane Preparations 
Strain  Encapsulation*  HAS 
(sp act  ~) 
WF50  +  18,648 
WF51  +  21,910 
WF13  +  23,942 
WF14  +  18,090 
WF15  -  59 
WF20  -  136 
WF22  -  125 
WF35  -  129 
WF61  -  156 
WF62  -  0 
WF63  +  12,345 
WF64  +  18,400 
* Encapsulation determined by India ink stain. 
*  Sp  act; pmol glucoronic acid transferred from UDP-glucuronic 
acid/h/mg of protein. 
tion fragments of 11.5 and 6.5 kb (Fig.  1 B, lane 2).  This 
hybridization pattern is distinct from that of WF61 DNA 
(Fig. 1 B, lane I). Thus, generalized transduction of the WF20 
and WF22 transconjugants resulted in two classes of acap- 
sular mutants, represented by the WF61 and WF62 trans- 
ductants. Southern analyses indicated that an insertion similar 
to that found in the WF62 class of transductant was present 
among the multiple copies of Tn916 in the WF15 and WF35 
transconjugant DNA  (data not shown). 
After the Tn916 insertions of the transductants were charac- 
terized, the HAS activity in the membranes of the two un- 
encapsulated mutants was assayed. As seen in Table 2, both 
the WF61 and WF62 mutants lacked  significant HAS ac- 
tivity (<1% relative to their respective parents). Mucoid trans- 
ductants were not tested as they produced a demonstrable 
capsule.  HAS assay of WF61 and WF62 confirmed, there- 
fore,  that the respective  Tn916 insertions were responsible 
for the loss of both capsule  production and HAS activity. 
Analysis and Cloning of  the WF61 DNA Flanking Tn916.  A 
probe for the DNA flanking Tn916 in the WF61 class of acap- 
sular transductants was generated by SSP-PCR amplification 
of group A streptococcal DNA.  Unlike conventional PCR 
amplification of genomic DNA, SSP-PCR requires only one 
specific primer. The template for SSP-PCR is constructed by 
restricted digestion of  genomic DNA and ligation to a known 
plasmid restriction fragment, followed by amplification in 
the presence  of a second, plasmid-specific  primer. Accord- 
ingly, the template for amplification of the WF61 left junc- 
tion  fragment was  constructed by ligation of completely 
Sau3AI-digested streptococcal DNA  to  BamHI-linearized 
pUC18 plasmid DNA. The SSP-PCR reaction was then car- 
ried out using the TNL1  primer in conjunction with the 
pUC18-specific primer. Agarose gel electrophoresis of the reac- 
tion mixture revealed a PCR product of "~0.75 kb (Fig.  2, 
lane 2). In addition to S. ~ogenes DNA, this PCR product 
possessed  the predicted pUC18  and Tn916 sequences  (data 
not shown). 
To further confirm that the amplified DNA did indeed 
flank the transposon in WF61, the product from the above 
PCR reaction was cloned and used as probe in Southern 
hybridizations. The PCR product was digested with both 
TaqI  and  PstI  and  then  ligated  to  ClaI-PstI-digested 
pBluescript. A 0.4-kb insert of amplified S. pyogenes DNA 
(and a small portion of the pUC18 polylinker) from one of 
the resultant chimeric plasmids (pGAC106)  was then 32p. 
labded  and  used  in  Southern  blot  hybridizations.  The 
pGAC106 probe hybridized to a 3.1-kb HindlII fragment of 
the wild-type WFS0 DNA (Fig. 3 A, lane 1), and the trans- 
Figure 1.  Southern  hybridization  ofS.  pyogenes  DNA to identify  Tn916- 
chromosome junction fragments. Whole-cell DNA was digested with 
Hindlll and probed with 32P-labeled  pAM120 plasmid. (A) Lane  1, WF51; 
lane 2, WF20; lane  3, a representative  encapsulated  transductant;  lane  4, 
WF61; lane  5, EcoRI-HindllI-digested  pAM120 (included  as a positive 
control). Size standards  (in kb) correspond to HindIII-digested  ~, DNA. 
(B) Whole-cell  streptococcal  DNA digested  and probed as in A. Lane  I, 
WF61; lane 2, WF62; lane 3, WF15. The sizes of hybridizing  WF61 
and WF62  junction  fragments  are indicated  at the left  and right,  respectively. 
Figure  2.  Amplification of 
S. pyogenes  DNA  by  PCR. 
Whole-cell DNA  from WF61 
was amplified  with the primers 
specific for the left terminus of 
Tn916 (TNL1, 5'-TATAAAGCT- 
TGAGAAGCAACAGGAGCG- 
~L-"I'TGTTGC-3'),  and for  pUC18 
(M13 - 47 primer, 5'-CGCCAG- 
C-GTITI'CCCAGTCACGAC-3'). 
After  30 cycles  of PCR, the reac- 
tion mixture was  separated by 
agarose gel  electrophoresis and 
visualized by ethidium bromide 
staining. Lane I,  1-kb ladder 
marker (Bethesda Research Lab- 
oratories); lane 2,  WF61 PCR. 
reaction mixture. 
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tam group A streptococcal  DNA. Whole-celt  DNA was digested with 
HindllI and probed  with (A) pGAC106, (B) pGAC126, and (C-)  pGAC130 
DNA. Lane I, WF51; lane  2, WF61; lane 3, WF62; lane 4, WF63. The 
1L5-kb band in C, lane 3 was visible upon prolonged exposure. 
ductant  WF62 DNA  (Fig.  3 A,  lane 3).  Hybridization  of 
the pGAC106 probe to WF61  DNA,  however, resulted in 
an  8.5-kb  HindlII  fragment  (Fig.  3  A,  lane  2).  This  hy- 
bridizing restriction fragment was approximately 5.4 kb larger 
than the wild-type fragment, indicating that the left terminus 
of Tn916 inserted  "3  kb from a HindlII  site in the WF61 
genome (see Fig. 4). The 8.5-kb fragment was also demon- 
strated in WF61 DNA when the transposon  was used as a 
probe (e.g., Fig.  1 B, lane 1), confirming that it was indeed 
the left HindllI junction  fragment. 
The  pGAC106  insert  was  then  employed  to  probe  a 
replacement vector library of WF14 DNA and identify a non- 
mutagenized copy of the DNA involved in capsule produc- 
tion.  Positive plaques  were obtained  at  a frequency of -1 
KH  H  K 
--  T~916  _--~  ~-~-_  Tn916  -- 
~  i_ wF62~.J  ~I~F6~_-  - 
H  S  H  HS  H  K 
pGAC126  ~  pGAC106 
VXH 
p~AC11~ 
=lkb 
Figure 4.  Restriction map of wild-type DNA for the locus involved 
in capsule production. ( ........ ) Orientation of the respective  Tng16 inser- 
tions of WF61 and WF62 (,~1/8 scale). (  ..... -) Position of the WF61 
deletion extends  approximately  2 kb beyond  the chromosomal  DNA illus- 
trated here. In WF6I and WF62, the transposon inserted into two open 
reading frames, ORFA and ORFB (,.-  designating  putative direction 
of transcription). Restriction  sites  are abbreviated  as follows:  H = Hindlll, 
K  =  Kpnl, S =  Sau3AI, V =  PvulI, and X  =  Xbal. For clarity, the 
only chromosomal  Sau3AI sites represented  (hatched  bars) are those  cloned 
into the ~, replacement vector  polylinker  in the construction of MID5 and 
KBD21. DNA subcloned  into pACYC184  from M3D5  and MID21 is indi- 
cated by the solid bars labeled  pGAC112 and pGAC130, respectively.  The 
DNA flanking the Tn916 insertions of WF61 and WF62 was amplified 
by PCR and cloned  into pBluescript to create the pGAC106  and pGAC126 
ptasmids, respectively. 
in 200. One positive clone (M~D5) was isolated and its DNA 
further analyzed. Sail digestion of the XBD5 DNA resulted 
in the expected )x DNA restriction  fragments,  as well as a 
fragment  of 12 kb, which corresponds  to the entire  strep- 
tococcal DNA  insert.  Digestion  of this  insert  with  XbaI 
yielded three restriction  fragments  of 5.2,  4.5,  and 2.2 kb. 
The 4.5-kb  XbaI fragment  hybridized  with  the pGAC106 
probe and was therefore cloned into the pACYC184 plasmid 
using SalI and XbaI. The pACYC184 vector was chosen to 
bypass potential  stability problems  of this  group  A  strep- 
tococcal insert in E. coli, as was reported by Kehoe and Timmis 
(34). Antibiotic sensitivity and DNA hybridization indicated 
that one recombinant plasmid,  pGAC112, contained the proper 
insert. 
Further  analysis  of pGAC112 indicated that  it contained 
internal  HindlII and KpnI restriction  sites separated by 1.4 
kb. The pGAC106 probe hybridized to a region proximal to 
this internal HindlII site, suggesting that Tn916 inserted ex- 
tremely close to a HindlII  site in WF61.  Restriction map- 
ping  and DNA  sequence analysis  of pGAC112  and  WF61 
has identified the insertion site of the transposon in WF61. 
This site is situated  125 bp from the HindlII  site  of wild- 
type DNA,  and is illustrated  in  Fig.  4.  Subsequent DNA 
hybridization  analyses  have  demonstrated,  however,  that 
genomic DNA has been deleted from this insertion  site to 
a region 6-8 kb distal from the right  terminus of Tn916 in 
WF61  (see below). 
Analysis and Cloning of the DNA Flanking the Tn916 Inser- 
tion of WF62.  A  probe was also generated for the WF62 
class of transductants by SSP-PCR amplification of DNA se- 
quences adjacent to the transposon.  A  template of HindlII- 
digested WF62 DNA ligated  to similarly digested pUC18 
DNA was amplified in the presence of the primers  specific 
for Tn916 (TNR1)  and pUC18 DNA.  This PCR reaction 
resulted in a 0.7-kb  product consisting of amplified S. py0- 
genes,  pUC18,  and  Tn9t6  (data not  shown). 
To clone the right Tngt6-chromosomaljunction  fragment 
of WF62, the PCR product was digested with HindlII, then 
ligated to HindllI-linearized pBluescript to create pGAC126. 
32p-labeled pGAC126  insert  was then  used to probe wild- 
type and mutant whole-cell DNA. The pGAC126 DNA hy- 
bridized  to a  1.2-kb HindlII  fragment  of wild-type DNA 
(WF51; Fig. 3 B, lane t) and to an 11.5-kb HindIII fragment 
of WF62 DNA  (Fig.  3 B,  lane 3).  The  latter band corre- 
sponds to the right Tng16 HindlIljunction fragment of WF62 
(see Fig.  1 B,  lane 3,  and  Fig.  4).  Surprisingly,  the WF61 
DNA  did not  hybridize with  the pGAC126 probe (Fig.  3 
B,  lane 2),  even upon  prolonged  exposure. 
The  pGAC126  probe was then  used  to  identify  a non- 
mutagenized  copy of the DNA  flanking  the  WF62 trans- 
poson insertion. Southern hybridizations were first performed 
with XBD5 DNA in an effort to determine if DNA homol- 
ogous to the pGAC126 probe resided in the hBD5 insert. 
The pGAC126 probe did not hybridize with XBD5 DNA, 
demonstrating  that the DNA inactivated by the transposon 
in WF62 was not yet doned. Therefore, radiolabeled pGAC126 
insert DNA was used to screen the X library of WF14 DNA. 
One positive clone ()xBD21) possessed 2 kb of DNA not in- 
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with XbaI and PvulI, and cloned into XbaI-EcoRV-digested 
pACYC184 to create pGAC130 (see Fig. 4). Further analysis 
indicated that in WF62, Tn916 inserted ~2.6 kb away from 
the transposon insertion site of WF61. This insertion appar- 
ently inactivated the gene product of an open reading frame 
(ORFA) which is oriented divergently from the open reading 
frame mutated in WF61,  and ORFB (see Fig.  4). 
Demonstration of  a Deletion in WF61.  The failure of WF61 
to hybridize with the pGAC106 probe (Fig. 3 B, lane 2) leads 
us to hypothesize that a deletion of genomic DNA had oc- 
curred. Further evidence for this deletion included the pres- 
ence of an unpredicted WF61 HindlII right junction frag- 
ment (a 17.5-kb band [Fig.  1 A, lane 4] is present instead 
of a predicted 11-kb band), as well as the amplification of 
a WF61 right junction PCR product containing DNA that 
did not correspond to the expected product (data not shown). 
Therefore the pGAC130 insert was used as a probe in DNA 
blots to estimate the extent of DNA deletion. As expected, 
the pGAC130 insert hybridized to wild-type HindlII frag- 
ments of 3.1, 2.2, 1.9, and 1.2 kb (Fig. 3 C, lane 1). Hybrid- 
ization of this probe to WF62 DNA results in hybridization 
of all but the 1.2-kb HindlII fragment, now replaced by the 
chromosome-transposon  junction fragments of 11.5 and 6.5 
kb (Fig.  3 C, lane 3; note that the 11.5-kb fragment was 
visible after prolonged exposure). The only hybridization of 
pGAC130 with WF61 DNA is the 8.5-kb left junction frag- 
ment (Fig. 3 C, lane 2), indicating that at least 5.6 kb of 
DNA beyond the right Tn916 terminus has been deleted from 
the genome (see Fig.  4). 
Reversion of Mutants to Capsule Production.  Revertants of 
Tn916-mutagenized group A streptococci have been isolated 
in the absence of selective pressure for the transposon (32). 
Accordingly, WF62 was passaged in media lacking tetracy- 
cline and plates were screened for mucoid colonies.  Plating 
of the WF62 stock directly onto media lacking the antibi- 
otic failed to result in encapsulated colonies ("~30,000 colo- 
nies were examined). An overnight passage of the acapsular 
WF62 mutant in liquid media was sufficient to recover roughly 
1 in 1,000 capsule-producing streptococci. Both Tc  ~ and Tc  ~ 
revertants  appeared, with the former being more frequently 
obtained "~83%  of the time. 
After isolation of encapsulated revertants,  Southern anal- 
yses were performed to determine if the transposon had ex- 
cised from ORFA. Whole-cell DNA was isolated from one 
Tc  r  revertant  (WF63)  and  hybridized  with  3~P-labeled 
pGAC126 insert. As seen in Fig. 3 B, WF63 now possesses 
the 1.2-kb HindlII fragment (lane 4). A wild-type pattern 
was also observed upon hybridization with pGAC130 (Fig. 
3 C, lane 4), and pGAC106  (Fig. 3 A, lane 4). DNA from 
a representative Tc  S  revertant (WF64) hybridized in a similar 
fashion with ORFA-specific probes (data not shown). Assay 
of WF63 and WF64 membranes indicated that HAS activity 
was restored (Table 2; sp act 12,345 and 18,400, respectively). 
Therefore, the encapsulated variants of WF62 examined no 
longer possessed a Tn916 insertion in ORFA and demonstrated 
HAS activity approaching that of the encapsulated group A 
streptococci. 
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Discussion 
In addition to the numerous studies that correlate  hy- 
aluronate capsule production with virulence of group A strep- 
tococci, the recovery of highly mucoid isolates from recent 
outbreaks of acute rheumatic fever emphasizes  the need to 
characterize the production of this polysaccharide. Using Tn916 
mutagenesis, nonmucoid transconjugant colonies were de- 
rived from mucoid strains of group A streptococci, and were 
shown to lack demonstrable capsule. None of the mutations 
characterized in this study affected the genes required for the 
production of the nucleotide-sugar precursors of hyaluronic 
acid. Since precursor nudeotide sugars are part of the HAS 
assay reaction mixture, membranes from a mutant of this class 
still should be able to produce hyaluronic acid. The back- 
ground levels of radiolabeled substrate incorporation indicated 
that all acapsular transconjugants possessed <1% of the HAS 
activity of encapsulated isolates. 
Because of the presence of multiple copies of the trans- 
poson in transconjugants, however, generalized transduction 
was required to establish linkage between the mutant pheno- 
type and a single Tn916 lesion. Two distinct classes of acapsu- 
lar, HAS- transductants resulted from these marker exchange 
studies, and further molecular analyses of the Tn916-inactivated 
DNA of WF61 and WF62 defined a locus required for HAS 
activity. Finally, the isolation of encapsulated WF62 variants 
with HAS activity approaching that of wild-type confirmed 
that the Tn916 insertion into ORFA was responsible for the 
loss of hyaluronate biosynthesis. The WF63 revertant appar- 
ently possessed two-thirds the HAS activity of its strepto- 
mycin-resistant parent, while the enzyme activity of WF64 
was equivalent to that of WF14. One possible explanation 
for the decrease in WF63 HAS activity is alteration of the 
ORFA sequence and thus the ORFA gene product. In any 
case, these experiments firmly established  the requirement 
for an intact ORFA in capsular  hyaluronate biosynthesis. 
This is the first report, of which we are aware, that demon- 
strates such a large deletion of host DNA accompanying a 
Tn916 insertion. The transposon appears to be intact based 
on restriction analyses and the sequences of Tn916 in the PCR 
products. Based upon restriction hybridization data of WF61 
versus wild-type DNA, the deletion is estimated to be ,v6-8 
kb. The transconjugant WF20 also harbored this deletion, 
which suggests that it did not occur during the transduction 
procedure. Our application of SSP-PCR to Tn916-mutagenesis 
studies provided a fast, convenient method for detecting the 
deletion. This technique will allow other researchers using 
Tn916 to rapidly generate probes for the inactivated DNA 
and sequence transposon-chromosome junction fragments. 
Although transposon mutagenesis implicates a role for 
ORFA in HAS activity,  one cannot exclude the possibility 
that the HAS- phenotype of WF62 results from the inter- 
ruption of transcription of downstream genes. The deletion 
that accompanied the Tn916 insertion of WF61 included the 
entire ORFA. It is probable that this deletion, rather than 
the disruption of ORFB, is responsible for the loss of HAS 
activity. It is also possible that other genes required for HAS 
activity were lost in WF61. However, the deletion may pro- vide a unique opportunity for complementation studies using 
the WF61 mutant. By reintroduction of various portions of 
the DNA lost in this transductant, enzyme activity should 
be fully restored upon addition of the proper combination 
of HAS genes. Experiments are currently in progress to ad- 
dress these points.  Another approach to demonstrate HAS 
activity involves expression of cloned genes in bacteria other 
than group A streptococci. Although most strains of E. coli 
do not synthesize the UDP-glucuronic acid precursor, an ex- 
ogenous source of this substrate is provided in the HAS assay. 
Preliminary studies with detergent-solubilized E. coli harboring 
pGAC130 suggest that we have yet to reconstitute enzyme 
activity. Besides the need to optimize the assay for other bac- 
teria, full expression of enzyme activity in heterologous hosts 
may require other HAS components and/or  streptococcal 
regulatory factors not present in the cloned DNA sequences. 
It has been suggested that the virR  gene (35)  regulates 
hyaluronate biosynthesis. Deletions in this gene, located up- 
stream of the M protein and C5a peptidase structural genes, 
result in decreased expression of these two surface-associated 
virulence factors. It was also demonstrated that variants har- 
boring deletions of virR  no longer expressed capsule.  Pre- 
liminary Southern hybridization studies performed in our lab- 
oratory indicate that virR is not closely linked to the locus 
required for HAS activity. Isolation and characterization of 
a larger sample of acapsular mutants should yield transposon 
insertions in virR if this gene truly regulates capsule produc- 
tion. In addition, quantitation of the levels of HAS-specific 
mRNA and HAS enzyme in virR mutants may provide more 
evidence for regulation of hyaluronate synthesis by this gene. 
An acapsular mutant (TX4) similar to the WF61 trans- 
ductant was recently derived from an M  type 18 group A 
streptococcal strain by Wessels et al.  (2).  DNA hybridiza- 
tion and sequence analysis performed by our laboratory indi- 
cates that WF61 and TX4 harbor the same deletion/inser- 
tion. Insertion into the same site can be explained by a preferred 
Tn916 target sequence in the genome of these S. t~ogenes 
strains.  However, the presence of the same deletion in these 
two independently isolated transductants is intriguing. It is 
possible  that factors produced by the transposon somehow 
interacted with sequences in the host genome and induced 
the deletion of intervening DNA. Another explanation in- 
volves recombination between the transposon in ORFB and 
a second copy of Tn916 situated 6-8 kb away. 
Liquid passage of WF61 has so far failed to result in en- 
capsulated revertants, and acapsular mutants possessing this 
deletion/insertion are presumably nonrevertable. It must be 
confirmed, however, that the deletion of such a significant 
portion of the genome has not affected other streptococcal 
factors. Passage of WF62 in the absence of tetracycline resulted 
in Tc  s- and Tc~-encapsulated revertants. S. ~ogenes variants, 
both sensitive  and resistant to the antibiotic, were also iso- 
lated by Nida and Cleary (32).  WF62 is also an important 
mutant for studies of hyaluronate synthesis since the Tn916 
insertion has not caused any detectable change in nearby DNA 
and includes the DNA deleted in WF61. However, an ideal 
isogenic mutant for future studies should be constructed by, 
for example, allelic replacement of genes required for capsule 
biosynthesis. On the basis of transposon mutagenesis, ORFA 
has been identified as an HAS gene in this study. Further 
analysis should determine which other regions of the group 
A streptococcal genome are required for hyaluronate synthesis. 
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